发明公开
- 专利标题： GUANIDINE COMPOUND
- 专利标题（中）： 胍
-
申请号： EP15191536.0申请日： 2012-03-13
-
公开(公告)号： EP3002278A1公开(公告)日： 2016-04-06
- 发明人: YOSHIHARA, Kousei , SUZUKI, Daisuke , YAMAKI, Susumu , YAMADA, Hiroyoshi , MIHARA, Hisashi , SEKI, Norio
- 申请人： Astellas Pharma Inc.
- 申请人地址： 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo 103-8411 JP
- 专利权人： Astellas Pharma Inc.
- 当前专利权人： Astellas Pharma Inc.
- 当前专利权人地址： 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo 103-8411 JP
- 代理机构： Bates, Philip Ian
- 优先权： JP2011056031 20110315
- 主分类号： C07D205/04
- IPC分类号： C07D205/04 ; A61K31/426 ; A61K31/4402 ; A61K31/4545 ; A61K31/495 ; A61K31/496 ; A61K31/505 ; A61K31/506 ; A61K31/5377 ; A61K31/551 ; A61P1/02 ; A61P1/04 ; A61P1/16 ; A61P3/04 ; A61P3/10 ; A61P9/00 ; A61P9/10 ; A61P9/12 ; A61P11/00
摘要：
[Problem]
The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases.
[Means for Solution]
The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.
The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases.
[Means for Solution]
The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.
公开/授权文献
- EP3002278B1 GUANIDINE COMPOUND 公开/授权日：2017-04-19
信息查询
